Evidence map›Paper›PMID 40836976›Full record

ArticleFrontiers in drug delivery2024

High-throughput drug screening to investigate blood-brain barrier permeability

Carolin J Curtaz, Sophia Wucherpfennig, Emad Al-Masnaea, Saskia-Laureen Herbert, Achim Wöckel, Patrick Meybohm, Malgorzata Burek

Abstract read
In one paragraph

Article in Frontiers in drug delivery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Anti-HER2-targeted therapies: effects on humanFrontiers in drug delivery · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carolin J CurtazUniversity Hospital Würzburg, Department of Gynecology and Obstetrics, Würzburg, Germany.
Sophia WucherpfennigUniversity Hospital Würzburg, Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, Würzburg, Germany.
Emad Al-MasnaeaUniversity Hospital Würzburg, Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, Würzburg, Germany.
Saskia-Laureen HerbertUniversity Hospital Würzburg, Department of Gynecology and Obstetrics, Würzburg, Germany.
Achim WöckelUniversity Hospital Würzburg, Department of Gynecology and Obstetrics, Würzburg, Germany.
Patrick MeybohmUniversity Hospital Würzburg, Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, Würzburg, Germany.
Malgorzata BurekUniversity Hospital Würzburg, Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, Würzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy of cerebral diseases such as brain metastatic breast cancer is still challenging. Due to the blood-brain barrier (BBB), a tight barrier that protects the brain and prevents the passage of many drugs, therapeutically sufficient drug concentrations in the brain are often not achieved. Therefore, methods and drugs to manipulate the BBB permeability are required. Here we used high-throughput screening (HTS) to identify chemicals that may increase BBB permeability. Human BBB

Indexed as

4-amino-1,8-naphthalimideblood-brain barrierGW2974high-throughput drug screeningin vitro modelsmetastatic breast cancer

Identifiers

PMID40836976
PMCPMC12363248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.